QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VIII Post-Authorisation Safety Studies

Test your understanding of the concepts covered by GVP Module VIII: Post-Authorisation Safety Studies Explained.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the MAH's responsibility when a PASS is outsourced?

The vendor assumes all regulatory accountability once the contract is signed The MAH remains responsible for applicable obligations and must maintain appropriate oversight The QPPV becomes the sole operational owner of the vendor Outsourcing converts the PASS into a voluntary study

Question 2 of 10 Which conclusion about prospective data collection is supported by the article?

Prospective collection automatically makes a study interventional Prospective collection is incompatible with PASS A study can collect data prospectively and still be non-interventional if the cumulative criteria are satisfied Prospective collection automatically makes a study an RMP commitment

Question 3 of 10 Which sequence best represents a controlled PASS lifecycle?

Study conduct, commercial launch, protocol, classification, final report Need or uncertainty, classification, objectives and protocol, conduct, analysis, reporting and regulatory follow-up Publication, signal closure, vendor selection, data collection and RMP creation Database selection, marketing decision, protocol deletion, analysis and registration

Question 4 of 10 What is the most appropriate role of the QPPV in relation to significant PASS activities?

Personally perform every data-management and statistical task Have appropriate oversight of important obligations, findings and implications within the pharmacovigilance system Approve every investigator's clinical decision Replace the regulatory affairs function for all submissions

Question 5 of 10 A PASS identifies evidence suggesting an important new safety concern. What is the most appropriate next step?

Disregard it because the study was voluntary Close the issue because the study has already ended Enter the information into normal safety assessment and escalation processes Publish the finding and wait for external confirmation before assessing it

Question 6 of 10 Which statement best explains why sophisticated statistical analysis cannot always compensate for weaknesses elsewhere in a PASS?

Statistical methods are irrelevant to PASS A weak regulatory question, poor data quality or inadequate exposure ascertainment may limit the evidence regardless of analytical sophistication Only descriptive analyses are allowed in PASS Statistical quality is determined solely by sample size

Question 7 of 10 An observational study uses electronic health records, but its protocol requires investigators to assign patients to treatment groups before prescribing. What is the key regulatory implication?

The study remains non-interventional because electronic records are used The study remains non-interventional because it is labelled observational The protocol-directed treatment assignment may place the study outside the non-interventional framework The study is automatically exempt from pharmacovigilance requirements

Question 8 of 10 Why should implementation of a risk-minimisation measure not be equated with its effectiveness?

Implementation data are always unreliable Delivery of a measure does not demonstrate that it changed knowledge, behaviour, clinical processes or outcomes Effectiveness can only be assessed in randomised clinical trials Risk-minimisation measures do not have measurable objectives

Question 9 of 10 Which example most clearly evaluates risk-minimisation effectiveness rather than merely implementation?

Recording that educational materials were distributed Counting the number of healthcare professionals who received a letter Assessing whether the intervention changed prescribing behaviour and reduced the targeted clinical outcome Documenting that the measure was included in the product information

Question 10 of 10 Why should a study's internal name not be used as its regulatory classification?

Internal names are prohibited under EU law Terms such as registry, observational study and real-world evidence study can describe activities with different regulatory purposes and designs Only competent authorities may name a study Study names determine whether data can be analysed

Knowledge Assessment: GVP Module VIII Post-Authorisation Safety Studies

Cookie Settings